| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.06 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.071 | 0.06 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.06 | 0.06 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.07 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.07 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.09 | 0.07 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.07 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.08 |
| mRNA | Roscovitine | GDSC1000 | pan-cancer | AAC | -0.095 | 0.08 |